Search

Walid Awni

from Seattle, WA
Age ~36
Get Report
Related to:
Al L SchultzAwni Nader, 36Alia AwniBetsy R Awni, 63W NaderHani Awni, 33Dorothy E Schultz
Connected to:
Kelcie N Awo, 38Prince I Awo, 41Mohamed Awod, 71Akinola Awofolaju, 62Martha S Awoke, 59John B Awokoya, 38Afolake M Awolaja, 60Remigious O Awolowo, 45Yawah Awolowo, 71Adesina Awonaike, 31

Walid Awni Phones & Addresses

  • Seattle, WA
  • 14105 Edgewater Ct, Lake Bluff, IL 60048 (847) 968-2066
  • Libertyville, IL
  • Lane, IL
  • 14105 Edgewater Ct, Libertyville, IL 60048 (312) 925-8792

Work

Position: Executive, Administrative, and Managerial Occupations

Education

Degree: Bachelor's degree or higher

Publications

Us Patents

Methods For Treating Hcv

View page
US Patent:
8466159, Jun 18, 2013
Filed:
Sep 4, 2012
Appl. No.:
13/603022
Inventors:
Barry M. Bernstein - Mequon WI, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
A61K 31/4965
A61K 31/33
A61K 31/505
A61K 31/47
A61K 31/415
A61K 31/40
US Classification:
51425505, 514183, 514269, 514314, 514397, 514309, 514394, 514422, 514 81
Abstract:
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e. g. , ritonavir), and ribavirin.

Methods For Treating Hcv

View page
US Patent:
8492386, Jul 23, 2013
Filed:
Sep 4, 2012
Appl. No.:
13/603006
Inventors:
Barry M. Bernstein - Mequon WI, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
A61K 31/4965
A61K 31/33
A61K 31/505
A61K 31/47
A61K 31/415
A61K 31/40
A61K 31/675
US Classification:
51425505, 514183, 514269, 514314, 514397, 514309, 514394, 514422, 514 81
Abstract:
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e. g. , ritonavir).

Methods For Treating Psoriasis Using Antibodies That Bind To The P40 Subunit Of Il-12 And/Or Il-23

View page
US Patent:
8557239, Oct 15, 2013
Filed:
Sep 14, 2010
Appl. No.:
12/881902
Inventors:
Joaquin Mario Valdes - Mundelein IL, US
Elliot K. Chartash - Marietta GA, US
William T. Barchuk - San Diego CA, US
Susan K. Paulson - Downers Grove IL, US
Kenneth B. Gordon - Northbrook IL, US
Walid M. Awni - Green Oaks IL, US
Yanjun Bao - Buffalo Grove IL, US
William G. Glass - Libertyville IL, US
Yihua Gu - Vernon Hills IL, US
Tom C. Harris - Gurnee IL, US
Martin Kaul - Neustadt, DE
Parvez M. Mulani - Gurnee IL, US
Peter Noertersheuser - Grosskarlbach, DE
Martin M. Okun - Libertyville IL, US
Assignee:
AbbVie Inc. - North Chicago IL
AbbVie Deutschland GmbH & Co. KG - Wiesbaden
International Classification:
A61K 39/395
US Classification:
4241301, 4241411, 4241421, 4241451, 514885, 514886
Abstract:
The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.

Methods For Administering Levosimendan

View page
US Patent:
20080070917, Mar 20, 2008
Filed:
Apr 27, 2007
Appl. No.:
11/741066
Inventors:
Roopal Thakkar - Grayslake IL, US
Leticia Delgado-Herrera - Lake Forest IL, US
Rajendra Pradhan - Buffalo Grove IL, US
Peter Noertersheuser - Groekarlbach, DE
Walid Awni - Green Oaks IL, US
Wenhui Zhang - Gurnee IL, US
International Classification:
A61K 31/50
A61P 9/00
US Classification:
514247000
Abstract:
The invention relates to a method of administering an inotropic agent (such as, but not limited to, a levosimendan compound) or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders.

Treatment Of Attention-Deficit/Hyperactivity Disorder

View page
US Patent:
20100144795, Jun 10, 2010
Filed:
May 29, 2009
Appl. No.:
12/475440
Inventors:
Earle E. Bain - Libertyville IL, US
Walid M. Abi-Saab - Dornach, CH
Sandeep Dutta - Gurnee IL, US
Tushar S. Garimella - Skokie IL, US
Walid M. Awni - Libertyville IL, US
Mario D. Saltarelli - Lake Bluff IL, US
Assignee:
ABBOTT LABORATORIES - Abbott Park IL
International Classification:
A61K 31/4439
A61P 25/00
US Classification:
514338
Abstract:
3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane and salts thereof are effective nicotinic receptor agonist compounds that demonstrated pharmacological effect for symptoms associated with attention-deficit/hyperactivity disorder.

Human Antibodies That Bind The P40 Subunit Of Human Il-12/Il-23 And Uses Therefor

View page
US Patent:
20120225080, Sep 6, 2012
Filed:
Jan 13, 2012
Appl. No.:
13/350472
Inventors:
Matthew W. Hruska - Lindenhurst IL, US
Susan K. Paulson - Downers Grove IL, US
Walid Awni - Libertyville IL, US
Peter Noertersheuser - Dirmstein, DE
Sven Mensing - Mannheim, DE
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 39/395
A61P 17/06
C07K 16/24
US Classification:
4241421, 53038815
Abstract:
The invention provides human antibodies that bind to the p40 subunit of human IL-12 and/or IL-23. The invention further provides a method of treating psoriasis in a subject by administering to a subject an antibody that binds to the p40 subunit of IL-12 and/or IL-23.

Methods For Treating Hcv

View page
US Patent:
20130102526, Apr 25, 2013
Filed:
Oct 19, 2012
Appl. No.:
13/656012
Inventors:
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Assignee:
ABBVIE INC. - North Chicago IL
International Classification:
A61K 38/07
A61P 31/14
A61K 31/7068
A61K 31/7072
A61K 38/06
US Classification:
514 43, 514 51, 514 48, 514 49
Abstract:
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Methods For Treating Hcv

View page
US Patent:
20130102557, Apr 25, 2013
Filed:
Oct 19, 2012
Appl. No.:
13/656024
Inventors:
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
A61K 31/7056
A61P 31/14
US Classification:
514 43
Abstract:
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Control profile
Walid Awni from Seattle, WA, age ~36 Get Report